These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 19439591)

  • 1. Immunization with amyloid-beta attenuates inclusion body myositis-like myopathology and motor impairment in a transgenic mouse model.
    Kitazawa M; Vasilevko V; Cribbs DH; LaFerla FM
    J Neurosci; 2009 May; 29(19):6132-41. PubMed ID: 19439591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta.
    Kitazawa M; Trinh DN; LaFerla FM
    Ann Neurol; 2008 Jul; 64(1):15-24. PubMed ID: 18318434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid-beta42 is preferentially accumulated in muscle fibers of patients with sporadic inclusion-body myositis.
    Vattemi G; Nogalska A; King Engel W; D'Agostino C; Checler F; Askanas V
    Acta Neuropathol; 2009 May; 117(5):569-74. PubMed ID: 19280202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenic accumulation of APP in fast twitch muscle of IBM patients and a transgenic model.
    Sugarman MC; Kitazawa M; Baker M; Caiozzo VJ; Querfurth HW; LaFerla FM
    Neurobiol Aging; 2006 Mar; 27(3):423-32. PubMed ID: 15950323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transgenic expression of beta-APP in fast-twitch skeletal muscle leads to calcium dyshomeostasis and IBM-like pathology.
    Moussa CE; Fu Q; Kumar P; Shtifman A; Lopez JR; Allen PD; LaFerla F; Weinberg D; Magrane J; Aprahamian T; Walsh K; Rosen KM; Querfurth HW
    FASEB J; 2006 Oct; 20(12):2165-7. PubMed ID: 16940437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD40L disruption enhances Abeta vaccine-mediated reduction of cerebral amyloidosis while minimizing cerebral amyloid angiopathy and inflammation.
    Obregon D; Hou H; Bai Y; Nikolic WV; Mori T; Luo D; Zeng J; Ehrhart J; Fernandez F; Morgan D; Giunta B; Town T; Tan J
    Neurobiol Dis; 2008 Feb; 29(2):336-53. PubMed ID: 18055209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives.
    Sigurdsson EM; Knudsen E; Asuni A; Fitzer-Attas C; Sage D; Quartermain D; Goni F; Frangione B; Wisniewski T
    J Neurosci; 2004 Jul; 24(28):6277-82. PubMed ID: 15254082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice.
    Kitazawa M; Green KN; Caccamo A; LaFerla FM
    Am J Pathol; 2006 Jun; 168(6):1986-97. PubMed ID: 16723713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production of IL-6 by human myoblasts stimulated with Abeta: relevance in the pathogenesis of IBM.
    Baron P; Galimberti D; Meda L; Scarpini E; Conti G; Cogiamanian F; Scarlato G
    Neurology; 2001 Nov; 57(9):1561-5. PubMed ID: 11706091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.
    Bruckmann S; Brenn A; Grube M; Niedrig K; Holtfreter S; von Bohlen und Halbach O; Groschup M; Keller M; Vogelgesang S
    Curr Alzheimer Res; 2017; 14(6):656-667. PubMed ID: 27915995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis.
    Jin LW; Hearn MG; Ogburn CE; Dang N; Nochlin D; Ladiges WC; Martin GM
    Am J Pathol; 1998 Dec; 153(6):1679-86. PubMed ID: 9846957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abeta immunotherapy protects morphology and survival of adult-born neurons in doubly transgenic APP/PS1 mice.
    Biscaro B; Lindvall O; Hock C; Ekdahl CT; Nitsch RM
    J Neurosci; 2009 Nov; 29(45):14108-19. PubMed ID: 19906959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sporadic inclusion-body myositis: conformational multifactorial ageing-related degenerative muscle disease associated with proteasomal and lysosomal inhibition, endoplasmic reticulum stress, and accumulation of amyloid-β42 oligomers and phosphorylated tau.
    Askanas V; Engel WK
    Presse Med; 2011 Apr; 40(4 Pt 2):e219-35. PubMed ID: 21392932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rabbits fed cholesterol-enriched diets exhibit pathological features of inclusion body myositis.
    Chen X; Ghribi O; Geiger JD
    Am J Physiol Regul Integr Comp Physiol; 2008 Mar; 294(3):R829-35. PubMed ID: 18216139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers.
    Fratta P; Engel WK; McFerrin J; Davies KJ; Lin SW; Askanas V
    Am J Pathol; 2005 Aug; 167(2):517-26. PubMed ID: 16049336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenic considerations in sporadic inclusion-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis.
    Askanas V; Engel WK; Nogalska A
    J Neuropathol Exp Neurol; 2012 Aug; 71(8):680-93. PubMed ID: 22805774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In AbetaPP-overexpressing cultured human muscle fibers proteasome inhibition enhances phosphorylation of AbetaPP751 and GSK3beta activation: effects mitigated by lithium and apparently relevant to sporadic inclusion-body myositis.
    Terracciano C; Nogalska A; Engel WK; Askanas V
    J Neurochem; 2010 Jan; 112(2):389-96. PubMed ID: 19878439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel demonstration of amyloid-β oligomers in sporadic inclusion-body myositis muscle fibers.
    Nogalska A; D'Agostino C; Engel WK; Klein WL; Askanas V
    Acta Neuropathol; 2010 Nov; 120(5):661-6. PubMed ID: 20711838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three lipoprotein receptors and cholesterol in inclusion-body myositis muscle.
    Jaworska-Wilczynska M; Wilczynski GM; Engel WK; Strickland DK; Weisgraber KH; Askanas V
    Neurology; 2002 Feb; 58(3):438-45. PubMed ID: 11839845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid-beta deposition in skeletal muscle of transgenic mice: possible model of inclusion body myopathy.
    Fukuchi K; Pham D; Hart M; Li L; Lindsey JR
    Am J Pathol; 1998 Dec; 153(6):1687-93. PubMed ID: 9846958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.